| WB | 咨询技术 | Rat |
| IF | 咨询技术 | Rat |
| IHC | 咨询技术 | Rat |
| ICC | 技术咨询 | Rat |
| FCM | 咨询技术 | Rat |
| Elisa | 咨询技术 | Rat |
| Aliases | CP35; PCN3; CYPIIIA5; P450PCN3 |
| WB Predicted band size | 57 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CYP3A5 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TrkB抗体的3篇参考文献及其简要摘要：
1. **"Selective antibody blockade of the TrkB neurotrophin receptor inhibits spatial memory formation"**
*作者：Klein, R. 等*
摘要：该研究开发了一种特异性阻断TrkB受体的抗体，证明其通过抑制BDNF/TrkB信号通路显著损害小鼠海马依赖的空间记忆形成，揭示了TrkB在记忆巩固中的关键作用。
2. **"TrkB monoclonal antibodies alter neuronal plasticity and protect dendrites from amyloid-β toxicity"**
*作者：Devi, L. 等*
摘要：研究报道了一种靶向TrkB胞外结构域的单克隆抗体，可增强神经元突触可塑性，并在阿尔茨海默病模型中减少Aβ诱导的树突损伤，提示TrkB抗体可能具有神经保护治疗潜力。
3. **"Antibody-induced activation of the TrkB receptor prevents cognitive deficits in a mouse model of Alzheimer's disease"**
*作者：Zeng, Y. 等*
摘要：通过TrkB激动型抗体激活下游信号通路，成功逆转了AD模型小鼠的认知功能衰退，表明TrkB抗体可能通过模拟BDNF功能改善神经退行性疾病病理。
(注：以上文献信息为示例性概括，实际引用需根据具体论文内容调整。)
Trk B antibodies are immunological tools designed to target and detect tropomyosin receptor kinase B (TrkB), a transmembrane receptor tyrosine kinase encoded by the *NTRK2* gene. TrkB is a high-affinity receptor for brain-derived neurotrophic factor (BDNF) and neurotrophin-4 (NT-4), playing critical roles in neuronal survival, differentiation, synaptic plasticity, and cognitive functions. Dysregulation of TrkB signaling is implicated in neurological disorders (e.g., Alzheimer’s disease, depression) and cancers, where aberrant activation via gene fusions or overexpression drives tumor progression.
Trk B antibodies are widely used in research to study TrkB expression, localization, and activation mechanisms. They enable techniques like Western blotting, immunohistochemistry, and flow cytometry, helping to identify TrkB isoforms (full-length or truncated) and phosphorylation states. Specificity is crucial, as TrkB shares homology with other Trk family members (TrkA, TrkC). Therapeutic anti-TrkB agents, including small-molecule inhibitors (e.g., larotrectinib) or monoclonal antibodies, are being explored to block oncogenic TrkB signaling in cancers with *NTRK2* alterations. However, challenges remain in ensuring selectivity and minimizing off-target effects in both research and clinical applications. These antibodies thus serve as vital reagents for unraveling TrkB's biological roles and advancing targeted therapies.
×
